Effects of the cholinomimetic drug arecoline upon aggression: Intra- vs. inter-specific allocation of attack

Systemic injections of cholinomimetic drugs have been reported to induce both rage and predatory attack in several species. In order to assess the relative contribution of each of these two behavioral patterns in the control of cholinergically induced attack, a group of adult female cats was chemically stimulated in the simultaneous presence of both a prey object and a conspecific attack object. In this choice situation stimulated cats initially tended to engage in rage attack. When a second group of subjects was tested in a successive choice situation a significantly greater number of attacks occurred against conspecifics. The results suggest that cholmergic stimulation initially induces affective attack, with somewhat less frequent incidents of predation.     

5HT antagonists attenuate MK801-impaired radial arm maze performance in rats

Glutamatergic hypofunction occurs in Alzheimer's disease (AD). MK801, a noncompetitive blocker of glutamate N-methyl-D-aspartate receptors, was used to disrupt the cognitive performance of rats trained on a delayed nonmatching to sample radial maze task. Drugs which act by blocking serotonin (5-HT) receptors were evaluated for their ability to reduce the cognitive impairment produced by MK801. Specifically, WAY-100635, a selective 5-HT1A receptor antagonist, buspirone, a 5-HT1A partial agonist, ritanserin, a 5-HT2 antagonist, and ondansetron, a 5-HT3 antagonist, were assessed. In addition, the muscarinic agonist arecoline was evaluated for its potential cognitive benefit in this model. It was found that WAY-100635 significantly reduced the cognitive impairment induced by MK801. Treatment with single doses of ritanserin, ondansetron, or arecoline in combination with MK801 did not result in a cognitive impairment, indicating that these drugs attenuated the MK801 impairment. The combination of buspirone and MK801 resulted in an inability of the animals to complete the task. These results suggest that interactions between 5-HT and glutamate may mediate the beneficial effects of reducing cognitive impairment and that 5-HT antagonists, especially selective 5-HT1A antagonists, may be useful in treating AD. Further, it is indicated that the MK801 model of cognitive impairment may add to the armamentarium of tools available to predict treatment efficacy in AD.